Details of the Drug

General Information of Drug (ID: DML2VSZ)

Drug Name

H3B-8800

Indication

Disease Entry	ICD 11	Status	REF
Myelodysplastic syndrome	2A37	Phase 2	[1]
Acute myeloid leukaemia	2A60	Phase 1	[2]
Chronic myelogenous leukaemia	2A20.0	Phase 1	[2]
Chronic myelomonocytic leukaemia	2A40	Phase 1	[3]
------------------------------------------------------------------------------------

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SF3b complex (SF3b)	TTXR78S	SF3B1_HUMAN-SF3B2_HUMAN-SF3B3_HUMAN-SF3B4_HUMAN-SF3B5_HUMAN-SF3B6_HUMAN	Modulator	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Targeting mRNA processing as an anticancer strategy. Nat Rev Drug Discov. 2020 Feb;19(2):112-129.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT02841540) A Study of H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia. U.S. National Institutes of Health.
4	Clinical pipeline report, company report or official report of H3 Biomedicine.